Clearmind Medicine Inc. Logo

Clearmind Medicine Inc.

CMND

(1.2)
Stock Price

1,20 USD

-90.87% ROA

-211.21% ROE

-0.64x PER

Market Cap.

5.354.361,00 USD

1.75% DER

0% Yield

0% NPM

Clearmind Medicine Inc. Stock Analysis

Clearmind Medicine Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Clearmind Medicine Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.45x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

4 ROE

The stock's ROE indicates a negative return (-315.62%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-176.97%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Clearmind Medicine Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Clearmind Medicine Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Clearmind Medicine Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Clearmind Medicine Inc. Revenue
Year Revenue Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Clearmind Medicine Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 646.487 100%
2022 2.984.677 78.34%
2023 1.055.816 -182.69%
2023 1.502.163 29.71%
2024 1.383.532 -8.57%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Clearmind Medicine Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2017 0
2018 254.535 100%
2019 105.283 -141.76%
2020 233.220 54.86%
2021 3.029.729 92.3%
2022 5.434.524 44.25%
2023 3.355.700 -61.95%
2023 4.794.061 30%
2024 4.501.460 -6.5%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Clearmind Medicine Inc. EBITDA
Year EBITDA Growth
2017 -6.670
2018 -254.535 97.38%
2019 -105.283 -141.76%
2020 -233.220 54.86%
2021 -3.450.426 93.24%
2022 -8.419.200 59.02%
2023 -6.354.868 -32.48%
2023 -6.119.190 -3.85%
2024 -3.229.808 -89.46%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Clearmind Medicine Inc. Gross Profit
Year Gross Profit Growth
2017 0
2018 0 0%
2019 0 0%
2020 0 0%
2021 -2.572 100%
2022 -113.379 97.73%
2023 0 0%
2023 -56.342 100%
2024 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Clearmind Medicine Inc. Net Profit
Year Net Profit Growth
2017 -6.671
2018 -194.535 96.57%
2019 -105.283 -84.77%
2020 -233.220 54.86%
2021 -4.122.652 94.34%
2022 -9.410.806 56.19%
2023 -2.300.748 -309.03%
2023 -8.445.917 72.76%
2024 -8.375.668 -0.84%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Clearmind Medicine Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2017 -1
2018 -18 100%
2019 -9 -125%
2020 -13 33.33%
2021 -133 90.98%
2022 -217 38.71%
2023 0 0%
2023 -42 100%
2024 -2 -1950%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Clearmind Medicine Inc. Free Cashflow
Year Free Cashflow Growth
2017 -27.546
2018 -236.760 88.37%
2019 -73.006 -224.3%
2020 -274.452 73.4%
2021 -3.066.218 91.05%
2022 -5.091.154 39.77%
2023 -4.577.305 -11.23%
2023 -1.375.655 -232.74%
2024 -1.126.741 -22.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Clearmind Medicine Inc. Operating Cashflow
Year Operating Cashflow Growth
2017 -9.124
2018 -105.588 91.36%
2019 -63.006 -67.58%
2020 -264.452 76.17%
2021 -2.835.029 90.67%
2022 -5.083.561 44.23%
2023 -4.577.305 -11.06%
2023 -1.375.655 -232.74%
2024 -1.126.741 -22.09%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Clearmind Medicine Inc. Capital Expenditure
Year Capital Expenditure Growth
2017 18.422
2018 131.172 85.96%
2019 10.000 -1211.72%
2020 10.000 0%
2021 231.189 95.67%
2022 7.593 -2944.76%
2023 0 0%
2023 0 0%
2024 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Clearmind Medicine Inc. Equity
Year Equity Growth
2017 63.329
2018 239.096 73.51%
2019 133.813 -78.68%
2020 499.293 73.2%
2021 4.801.828 89.6%
2022 -1.509.572 418.09%
2023 2.827.671 153.39%
2023 714.380 -295.82%
2024 3.472.922 79.43%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Clearmind Medicine Inc. Assets
Year Assets Growth
2017 129.122
2018 246.739 47.67%
2019 178.380 -38.32%
2020 512.656 65.2%
2021 5.158.983 90.06%
2022 1.127.974 -357.37%
2023 4.488.441 74.87%
2023 4.324.389 -3.79%
2024 8.173.364 47.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Clearmind Medicine Inc. Liabilities
Year Liabilities Growth
2017 65.793
2018 7.643 -760.83%
2019 44.567 82.85%
2020 13.363 -233.51%
2021 357.155 96.26%
2022 2.637.546 86.46%
2023 1.660.770 -58.81%
2023 3.610.008 54%
2024 4.700.442 23.2%

Clearmind Medicine Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-2.06
Price to Earning Ratio
-0.64x
Price To Sales Ratio
0x
POCF Ratio
-1.09
PFCF Ratio
-1.24
Price to Book Ratio
1.35
EV to Sales
0
EV Over EBITDA
0.64
EV to Operating CashFlow
0.52
EV to FreeCashFlow
0.52
Earnings Yield
-1.56
FreeCashFlow Yield
-0.81
Market Cap
0,01 Bil.
Enterprise Value
0,00 Bil.
Graham Number
6.72
Graham NetNet
0.88

Income Statement Metrics

Net Income per Share
-2.06
Income Quality
0.59
ROE
-2.11
Return On Assets
-0.9
Return On Capital Employed
-1.21
Net Income per EBT
1.04
EBT Per Ebit
1.66
Ebit per Revenue
0
Effective Tax Rate
-0.04

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.22
Free CashFlow per Share
-1.22
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-1.06
Return on Tangible Assets
-0.91
Days Sales Outstanding
0
Days Payables Outstanding
25496.96
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.01
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
2,16
Book Value per Share
0,98
Tangible Book Value per Share
0.94
Shareholders Equity per Share
0.98
Interest Debt per Share
0.02
Debt to Equity
0.02
Debt to Assets
0.01
Net Debt to EBITDA
2.15
Current Ratio
1.71
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
3491258
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-159814
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Clearmind Medicine Inc. Dividends
Year Dividends Growth

Clearmind Medicine Inc. Profile

About Clearmind Medicine Inc.

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

CEO
Dr. Adi Zuloff-Shani Ph.D.
Employee
4
Address
1220 West 6th Avenue
Vancouver, V6H 1A5

Clearmind Medicine Inc. Executives & BODs

Clearmind Medicine Inc. Executives & BODs
# Name Age
1 Dr. Adi Zuloff-Shani Ph.D.
Chief Executive Officer
70
2 Ms. Adi Varon
Controller
70
3 Prof. Mark Haden M.S.W.
Vice President of Business Development
70
4 Ms. Mylene Touboul
Accounting Manager
70

Clearmind Medicine Inc. Competitors